aTyr Pharma (NASDAQ:LIFE – Get Free Report) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
Several other analysts have also commented on the stock. Piper Sandler lifted their price objective on shares of aTyr Pharma from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 11th. Oppenheimer lowered shares of aTyr Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.
aTyr Pharma Stock Down 3.0 %
Shares of NASDAQ LIFE opened at $1.93 on Wednesday. aTyr Pharma has a 1 year low of $1.56 and a 1 year high of $4.28. The stock has a market capitalization of $104.78 million, a P/E ratio of -1.33 and a beta of 1.22. The company has a 50-day moving average price of $2.25 and a 200-day moving average price of $2.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.75 and a quick ratio of 8.75.
Insider Buying and Selling
In other news, Director Paul Schimmel bought 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 10th. The shares were acquired at an average price of $2.25 per share, with a total value of $450,000.00. Following the acquisition, the director now owns 313,023 shares of the company’s stock, valued at approximately $704,301.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.14% of the stock is currently owned by insiders.
Hedge Funds Weigh In On aTyr Pharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Federated Hermes Inc. grew its stake in aTyr Pharma by 94.8% in the 1st quarter. Federated Hermes Inc. now owns 10,189,966 shares of the biotechnology company’s stock worth $21,399,000 after buying an additional 4,958,366 shares in the last quarter. FMR LLC grew its stake in aTyr Pharma by 83.3% in the 1st quarter. FMR LLC now owns 7,974,307 shares of the biotechnology company’s stock worth $16,746,000 after buying an additional 3,622,900 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in aTyr Pharma in the 1st quarter worth approximately $10,134,000. Alyeska Investment Group L.P. grew its stake in aTyr Pharma by 79.4% in the 1st quarter. Alyeska Investment Group L.P. now owns 2,473,154 shares of the biotechnology company’s stock worth $5,194,000 after buying an additional 1,094,407 shares in the last quarter. Finally, Samsara BioCapital LLC purchased a new position in aTyr Pharma in the 1st quarter worth approximately $3,675,000. Hedge funds and other institutional investors own 71.88% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Read More
- Five stocks we like better than aTyr Pharma
- Green Hydrogen Stocks Getting Ready to Deliver Big Gains
- Charles Schwab Gets The Rebound, Time to Buy?
- Is Ebix Inc a Phygital E-Commerce Contender or Pretender?
- 3 Mid-Cap Stocks with Expectations for High-Earnings Growth
- Can Lockheed Martin Fly To A New High In 2023?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
